drugset / Trial / NCT00004890
Biomed 101 and Interleukin-2 in Treating Patients With Kidney Cancer
Treatment
Summary
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells. Biomed 101 may protect normal cells from the side effects of interleukin-2. PURPOSE: Phase I trial to study the effectiveness of Biomed 101 in treating patients receiving interleukin-2 for kidney cancer.
Timeline
- Start
- 2000-12
- Primary completion
- 2002-12
- Completion
- 2002-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Biomed 101 | Unknown | — | Oral |
| Background | aldesleukin | Protein / enzyme biologic | — | Intravenous |